Study Finds Modest Reality of Immunotherapy for Cancer

This study quantifies the disturbing trend that, despite the expansion in the number of patients eligible for expensive and potentially toxic ICIs [immune checkpoint inhibitors], the ratio of those benefiting is decreasing,” wrote Dr. Daniel V.T. Catenacci, co-author of an editorial that accompanied the study in JAMA Network. “Observations in this article are sobering and remind us to keep expectations realistic.” Both Catenacci and Haslem agreed that the study should serve as a reminder to patients, physicians and policy makers to have more realistic discussions about the use of, and expectations of, these immunotherapy drugs. “We hope these results will motivate researchers to develop drugs that benefit an even larger percentage of individuals with cancer than these current estimates,” the study concludes. The post Study Finds Modest Reality of Immunotherapy for Cancer appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news